{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:03:27Z","timestamp":1783605807085,"version":"3.55.0"},"reference-count":91,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Epithelial ovarian cancer (EOC) encompasses ovarian, fallopian tube and peritoneal malignancies. It is a deadly disease and is rarely cured when diagnosed at advanced stages. Early-stage disease is often curable, but clinicians and researchers have been stymied in their attempts to reliably screen for this disease, even in high-risk populations. Effective prevention of ovarian cancer is usually limited to the use of combined oral contraceptives and removal of the ovaries and fallopian tubes. Methods and Results: We aim to review the current guidelines and the evidence reported for both the early detection and prevention of ovarian cancer. Novel imaging techniques, biomarkers, and surgical advances will be discussed. Conclusions: This review will offer (a) an understanding of the epidemiology of EOC (b) analysis and a discussion of relevant molecular markers that might be exploited for more accurate early detection (c) medical and surgical methods to prevent ovarian cancer.<\/jats:p>","DOI":"10.3390\/cancers17244006","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:47:26Z","timestamp":1765889246000},"page":"4006","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Early Detection and Prevention of Ovarian Cancer"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8724-6622","authenticated-orcid":false,"given":"Lauren","family":"Montemorano","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Kaiser Permanente, Oakland, CA 94611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Huffman","sequence":"additional","affiliation":[{"name":"Carbone Cancer Center, University of Wisconsin, Madison, WI 53792, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9315-2414","authenticated-orcid":false,"given":"Lisa","family":"Barroilhet","sequence":"additional","affiliation":[{"name":"Carbone Cancer Center, University of Wisconsin, Madison, WI 53792, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"ref_1","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/1097-0142(20001115)89:10<2068::AID-CNCR6>3.0.CO;2-Z","article-title":"Ovarian carcinoma diagnosis","volume":"89","author":"Goff","year":"2000","journal-title":"Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ijgo.13878","article-title":"Cancer of the ovary, fallopian tube, and peritoneum: 2021 update","volume":"155","author":"Berek","year":"2021","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_4","first-page":"284","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1158\/1055-9965.EPI-23-0041","article-title":"Germline Mutations in 12 Genes and Risk of Ovarian Cancer in Three Population-Based Cohorts","volume":"32","author":"Kotsopoulos","year":"2023","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.19.02960","article-title":"Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline","volume":"38","author":"Konstantinopoulos","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bpobgyn.2016.08.006","article-title":"Epidemiology of epithelial ovarian cancer","volume":"41","author":"Webb","year":"2017","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/PAS.0b013e3181868904","article-title":"Serous tubal intraepithelial carcinoma and the dominant ovarian mass: Clues to serous tumor origin?","volume":"33","author":"Roh","year":"2009","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/GCO.0b013e328011a21f","article-title":"The distal fallopian tube: A new model for pelvic serous carcinogenesis","volume":"19","author":"Crum","year":"2007","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ctrv.2018.06.004","article-title":"Fallopian tube tumorigenesis and clinical implications for ovarian cancer risk-reduction","volume":"69","author":"Gockley","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1056\/NEJMra021902","article-title":"Rules for making human tumor cells","volume":"347","author":"Hahn","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/172460089801300402","article-title":"CA 125: The past and the future","volume":"13","author":"Bast","year":"1998","journal-title":"Int. J. Biol. Markers"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1136\/jcp.2004.018077","article-title":"The role of CA125 in clinical practice","volume":"58","author":"Moss","year":"2005","journal-title":"J. Clin. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13048-019-0503-7","article-title":"Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review","volume":"12","author":"Dochez","year":"2019","journal-title":"J. Ovarian Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jama.2025.9495","article-title":"Ovarian Cancer: A Review","volume":"334","author":"Caruso","year":"2025","journal-title":"JAMA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2007.10.017","article-title":"The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass","volume":"108","author":"Moore","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1158\/1940-6207.CAPR-10-0195","article-title":"Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens","volume":"4","author":"Cramer","year":"2011","journal-title":"Cancer Prev. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1158\/1078-0432.CCR-16-0316","article-title":"A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort","volume":"22","author":"Terry","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.trecan.2017.02.003","article-title":"Autoantibodies: Opportunities for Early Cancer Detection","volume":"3","author":"Macdonald","year":"2017","journal-title":"Trends Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1097\/AOG.0000000000000484","article-title":"Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer","volume":"124","author":"Erickson","year":"2014","journal-title":"Obstet. Gynecol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1158\/1078-0432.CCR-17-0284","article-title":"Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer","volume":"23","author":"Yang","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3233\/CBM-190988","article-title":"Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53","volume":"27","author":"Hurley","year":"2020","journal-title":"Cancer Biomark."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ygyno.2017.07.138","article-title":"Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection","volume":"147","author":"Fortner","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ygyno.2005.12.011","article-title":"Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer","volume":"102","author":"Lokshin","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.1002\/jcp.27486","article-title":"An overview of microRNAs: Biology, functions, therapeutics, and analysis methods","volume":"234","author":"Saliminejad","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Kan, C.W., Hahn, M.A., Gard, G.B., Maidens, J., Huh, J.Y., Marsh, D.J., and Howell, V.M. (2012). Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer, 12.","DOI":"10.1186\/1471-2407-12-627"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"104381","DOI":"10.1016\/j.yexmp.2020.104381","article-title":"miRNA profile in ovarian cancer","volume":"113","author":"Shoorei","year":"2020","journal-title":"Exp. Mol. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"89811","DOI":"10.18632\/oncotarget.20688","article-title":"A combination of circulating miRNAs for the early detection of ovarian cancer","volume":"8","author":"Yokoi","year":"2017","journal-title":"Oncotarget"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Zheng, H., Zhang, L., Zhao, Y., Yang, D., Song, F., Wen, Y., Hao, Q., Hu, Z., Zhang, W., and Chen, K. (2013). Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0077853"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"12339","DOI":"10.1007\/s13277-014-2546-0","article-title":"MiR-25 promotes ovarian cancer proliferation and motility by targeting LATS2","volume":"35","author":"Feng","year":"2014","journal-title":"Tumour Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/15592294.2016.1273308","article-title":"Mutual regulation of microRNAs and DNA methylation in human cancers","volume":"12","author":"Wang","year":"2017","journal-title":"Epigenetics"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1158\/1078-0432.CCR-05-2563","article-title":"Ovarian cancer biomarkers in urine","volume":"12","author":"Chambers","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_33","first-page":"200","article-title":"Osteopontin as a Tumor Marker in Ovarian Cancer","volume":"13","author":"Rani","year":"2022","journal-title":"J. Midlife Health"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"9660","DOI":"10.18632\/oncotarget.14173","article-title":"Diagnostic accuracy of urine HE4 in patients with ovarian cancer: A meta-analysis","volume":"8","author":"Jia","year":"2017","journal-title":"Oncotarget"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3233\/CBM-150457","article-title":"Increases urinary HMGA1 in serous epithelial ovarian cancer patients","volume":"15","author":"Zhou","year":"2015","journal-title":"Cancer Biomark."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"48832","DOI":"10.18632\/oncotarget.9453","article-title":"Circulating tumor DNA: A promising biomarker in the liquid biopsy of cancer","volume":"7","author":"Cheng","year":"2016","journal-title":"Oncotarget"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","article-title":"Liquid biopsy and minimal residual disease\u2014Latest advances and implications for cure","volume":"16","author":"Pantel","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"136ra68","DOI":"10.1126\/scitranslmed.3003726","article-title":"Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA","volume":"4","author":"Forshew","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1126\/science.aar3247","article-title":"Detection and localization of surgically resectable cancers with a multi-analyte blood test","volume":"359","author":"Cohen","year":"2018","journal-title":"Science"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"10732748241255548","DOI":"10.1177\/10732748241255548","article-title":"Ovarian Cancer Diagnosis and Prognosis Based on Cell-Free DNA Methylation","volume":"31","author":"Gao","year":"2024","journal-title":"Cancer Control"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13073-017-0500-7","article-title":"The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer","volume":"9","author":"Widschwendter","year":"2017","journal-title":"Genome Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2174\/1874467213666200810141858","article-title":"DNA Methylation in Epithelial Ovarian Cancer: Current Data and Future Perspectives","volume":"14","author":"Papakonstantinou","year":"2021","journal-title":"Curr. Mol. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41585-020-0286-z","article-title":"The microbiome and gynaecological cancer development, prevention and therapy","volume":"17","author":"Ilhan","year":"2020","journal-title":"Nat. Rev. Urol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Siddiqui, R., Makhlouf, Z., Alharbi, A.M., Alfahemi, H., and Khan, N.A. (2022). The Gut Microbiome and Female Health. Biology, 11.","DOI":"10.3390\/biology11111683"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s10020-021-00295-2","article-title":"The role of the microbiome in ovarian cancer: Mechanistic insights into oncobiosis and to bacterial metabolite signaling","volume":"27","author":"Sipos","year":"2021","journal-title":"Mol. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jmig.2014.03.017","article-title":"Brush cytology of the fallopian tube and implications in ovarian cancer screening","volume":"21","author":"Lum","year":"2014","journal-title":"J. Minim. Invasive Gynecol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2015.61.3083","article-title":"Lavage of the Uterine Cavity for Molecular Detection of M\u00fcllerian Duct Carcinomas: A Proof-of-Concept Study","volume":"33","author":"Maritschnegg","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12935-016-0354-x","article-title":"Cytologic studies of the fallopian tube in patients undergoing salpingo-oophorectomy","volume":"16","author":"Chen","year":"2016","journal-title":"Cancer Cell Int."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/bjc.2013.402","article-title":"Early detection of ovarian and fallopian tube cancer by examination of cytological samples from the endometrial cavity","volume":"109","author":"Otsuka","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1159\/000353825","article-title":"Cytologic findings in experimental in vivo fallopian tube brush specimens","volume":"57","author":"Rodriguez","year":"2013","journal-title":"Acta Cytol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"eaap8793","DOI":"10.1126\/scitranslmed.aap8793","article-title":"Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers","volume":"10","author":"Wang","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"167ra4","DOI":"10.1126\/scitranslmed.3004952","article-title":"Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers","volume":"5","author":"Kinde","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1177\/02841851211038808","article-title":"Ultrasound-stimulated microbubbles enhances radiosensitivity of ovarian cancer","volume":"63","author":"Ba","year":"2022","journal-title":"Acta Radiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1200\/JCO.2016.70.8594","article-title":"Ultrasound Molecular Imaging with BR55 in Patients with Breast and Ovarian Lesions: First-in-Human Results","volume":"35","author":"Willmann","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2016.12.032","article-title":"Ultrasound-mediated destruction of oxygen and paclitaxel loaded dual-targeting microbubbles for intraperitoneal treatment of ovarian cancer xenografts","volume":"391","author":"Luo","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11912-019-0816-0","article-title":"Novel Approaches to Ovarian Cancer Screening","volume":"21","author":"Nebgen","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1148\/radiol.13122053","article-title":"Ovarian carcinoma: Quantitative biexponential MR imaging relaxometry reveals the dynamic recruitment of ferritin-expressing fibroblasts to the angiogenic rim of tumors","volume":"268","author":"Vandsburger","year":"2013","journal-title":"Radiology"},{"key":"ref_59","first-page":"296","article-title":"Magnetic resonance relaxometry improves the accuracy of conventional MRI in the diagnosis of endometriosis-associated ovarian cancer: A case report","volume":"11","author":"Matsubara","year":"2019","journal-title":"Mol. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Kawahara, N., Kobayashi, H., Maehana, T., Iwai, K., Yamada, Y., Kawaguchi, R., Takahama, J., Marugami, N., Nishi, H., and Sakai, Y. (2024). MR Relaxometry for Discriminating Malignant Ovarian Cystic Tumors: A Prospective Multicenter Cohort Study. Diagnostics, 14.","DOI":"10.3390\/diagnostics14111069"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Lawton, F.G., and Pavlik, E.J. (2022). Perspectives on Ovarian Cancer 1809 to 2022 and Beyond. Diagnostics, 12.","DOI":"10.3390\/diagnostics12040791"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.fertnstert.2023.11.031","article-title":"Complications after opportunistic salpingectomy compared with tubal ligation at cesarean section: A retrospective cohort study","volume":"121","author":"Rufin","year":"2024","journal-title":"Fertil. Steril."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/AOG.0000000000005118","article-title":"Postpartum Opportunistic Salpingectomy Compared with Bilateral Tubal Ligation After Vaginal Delivery for Ovarian Cancer Risk Reduction: A Cost-Effectiveness Analysis","volume":"141","author":"Wagar","year":"2023","journal-title":"Obstet. Gynecol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/AOG.0000000000004285","article-title":"Postpartum Salpingectomy Compared with Standard Tubal Ligation After Vaginal Delivery","volume":"137","author":"Wagar","year":"2021","journal-title":"Obstet. Gynecol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"85.e1","DOI":"10.1016\/j.ajog.2018.10.016","article-title":"Menopausal symptoms and surgical complications after opportunistic bilateral salpingectomy, a register-based cohort study","volume":"220","author":"Collins","year":"2019","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"425.e416","DOI":"10.1016\/j.ajog.2017.06.004","article-title":"Persistence of fimbrial tissue on the ovarian surface after salpingectomy","volume":"217","author":"Gan","year":"2017","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1136\/ijgc-2023-004377","article-title":"TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: The TUBA-WISP II study protocol","volume":"33","author":"Steenbeek","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_68","first-page":"16","article-title":"NRG-CC008: A nonrandomized prospective clinical trial comparing the non-inferiority of salpingectomy to salpingo-oophorectomy to reduce the risk of ovarian cancer among BRCA1 carriers [SOROCk]","volume":"40","author":"Huh","year":"2022","journal-title":"Am. Soc. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/ijgc-2020-001541","article-title":"Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal (PROTECTOR): Protocol for a prospective non-randomised multi-center trial","volume":"31","author":"Gaba","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"dju410","DOI":"10.1093\/jnci\/dju410","article-title":"Ovarian cancer risk after salpingectomy: A nationwide population-based study","volume":"107","author":"Falconer","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e002845","DOI":"10.1136\/bmjopen-2013-002845","article-title":"Salpingectomy as standard at hysterectomy? A Danish cohort study, 1977\u20132010","volume":"3","author":"Guldberg","year":"2013","journal-title":"BMJ Open"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13063-018-3083-8","article-title":"Hysterectomy and opportunistic salpingectomy (HOPPSA): Study protocol for a register-based randomized controlled trial","volume":"20","author":"Idahl","year":"2019","journal-title":"Trials"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0361-090X(02)00004-1","article-title":"Oral contraceptives and risk of familial breast cancer","volume":"26","author":"Heimdal","year":"2002","journal-title":"Cancer Detect. Prev."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Jahanfar, S., Mortazavi, J., Lapidow, A., Cu, C., Al Abosy, J., Morris, K., Becerra-Mateus, J.C., Steinfeldt, M., Maurer, O., and Bohang, J. (2024). Assessing the impact of contraceptive use on reproductive cancer risk among women of reproductive age-a systematic review. Front. Glob. Womens Health, 5.","DOI":"10.3389\/fgwh.2024.1487820"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(08)60167-1","article-title":"Ovarian cancer and oral contraceptives: Collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls","volume":"371","author":"Beral","year":"2008","journal-title":"Lancet"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/AOG.0000000000003463","article-title":"Intrauterine Device Use and Ovarian Cancer Risk: A Systematic Review and Meta-analysis","volume":"134","author":"Wheeler","year":"2019","journal-title":"Obstet. Gynecol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ygyno.2016.04.543","article-title":"Is aspirin use associated with a decreased risk of ovarian cancer? A systematic review and meta-analysis of observational studies with dose-response analysis","volume":"142","author":"Zhang","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/jnci\/djy100","article-title":"Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium","volume":"111","author":"Trabert","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e230666","DOI":"10.1001\/jamanetworkopen.2023.0666","article-title":"Association of Frequent Aspirin Use with Ovarian Cancer Risk According to Genetic Susceptibility","volume":"6","author":"Hurwitz","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"djt431","DOI":"10.1093\/jnci\/djt431","article-title":"Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: A pooled analysis in the Ovarian Cancer Association Consortium","volume":"106","author":"Trabert","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0140-6736(20)30366-4","article-title":"Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: A double-blind, randomised, placebo-controlled trial","volume":"395","author":"Burn","year":"2020","journal-title":"Lancet"},{"key":"ref_82","first-page":"903","article-title":"Regular use of analgesic drugs and ovarian cancer risk","volume":"10","author":"Moysich","year":"2001","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1592\/phco.22.5.303.33189","article-title":"Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer","volume":"22","author":"Meier","year":"2002","journal-title":"Pharmacotherapy"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1158\/1940-6207.CAPR-21-0090","article-title":"Common Analgesic Use for Menstrual Pain and Ovarian Cancer Risk","volume":"14","author":"Sasamoto","year":"2021","journal-title":"Cancer Prev. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.2174\/1567205020666221114112814","article-title":"Targeting the Cancer Stem Cells in Endocrine Cancers with Phytochemicals","volume":"22","author":"Gor","year":"2022","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1016\/j.semcancer.2015.02.007","article-title":"Cancer prevention and therapy through the modulation of the tumor microenvironment","volume":"35","author":"Casey","year":"2015","journal-title":"Semin. Cancer Biol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/bph.13625","article-title":"Carotenoids: Biochemistry, pharmacology and treatment","volume":"174","author":"Milani","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Xu, X.L., Deng, S.L., Lian, Z.X., and Yu, K. (2021). Resveratrol Targets a Variety of Oncogenic and Oncosuppressive Signaling for Ovarian Cancer Prevention and Treatment. Antioxidants, 10.","DOI":"10.3390\/antiox10111718"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1021\/jf400192v","article-title":"Silibinin inhibits tumor growth through downregulation of extracellular signal-regulated kinase and Akt in vitro and in vivo in human ovarian cancer cells","volume":"61","author":"Cho","year":"2013","journal-title":"J. Agric. Food Chem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/jnci\/93.7.486","article-title":"Retinoids for ovarian cancer prevention: Laboratory data set the stage for thoughtful clinical trials","volume":"93","author":"Veronesi","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Kapur, A., Mehta, P., Simmons, A.D., Ericksen, S.S., Mehta, G., Palecek, S.P., Felder, M., Stenerson, Z., Nayak, A., and Dominguez, J.M.A. (2022). Atovaquone: An Inhibitor of Oxidative Phosphorylation as Studied in Gynecologic Cancers. Cancers, 14.","DOI":"10.3390\/cancers14092297"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/24\/4006\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:55:51Z","timestamp":1765889751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/24\/4006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":91,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["cancers17244006"],"URL":"https:\/\/doi.org\/10.3390\/cancers17244006","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]}}}